
3 Drug Ingredients Maker, Garments Exporter and Luxury Hotels Operator Stocks With a Strong Future Roadmap: Laurus Labs, Pearl Global Industries and Indian Hotels Company
Laurus Labs, Pearl Global Industries and Indian Hotels Company: ROE of 16.0% to 19.0% and FY22 to FY26 revenue CAGR of 8.5% to 32.7%. Prices as of 17 Nov 2026.
Updated: 18 Nov 2026 • 3:26 pm
Posted by:

Quick Answer
The three API maker, garment exporter and hotel stocks to watch are Laurus Labs, Pearl Global Industries and Indian Hotels Company. Their return on equity ranges from 16.0% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 32.7%. Pearl Global Industries has the highest return on equity at 19.0%, while Indian Hotels Company has the fastest revenue growth at 32.7% a year. Prices are based on the 17 November 2026 close, and this article is educational, not investment advice.
API maker, garment exporter and hotel stocks offer a focused view of a sector where demand keeps widening. Laurus Labs, Pearl Global Industries and Indian Hotels Company cover a drug ingredients maker, a garments exporter and a luxury hotels operator.
This list covers three API maker, garment exporter and hotel stocks with complete current figures: Laurus Labs, Pearl Global Industries and Indian Hotels Company. Every figure comes from the latest reported financials and the 17 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are API Maker, Garment Exporter and Hotel Stocks?
API maker, garment exporter and hotel stocks are listed companies that make active drug ingredients and finished medicines for global pharma firms, make ready made garments for international brands, and run luxury and premium hotels across India. Their earnings depend on drug orders, garment export orders and hotel demand.
API Maker, Garment Exporter and Hotel Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Laurus Labs | 2,338 | 111,434 | 102.2 | 36.0 | 16.8 | 0.48 |
| Pearl Global Industries | 1,368.2 | 11,806 | 38.9 | 35.2 | 19.0 | 0.65 |
| Indian Hotels Company | 901.55 | 108,181 | 46.9 | 37.9 | 16.0 | 0.22 |
On valuation, all three trade at a P/E above their industry P/E, which reflects the growth the market already expects from them. Readers comparing API maker, garment exporter and hotel stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in API maker, garment exporter and hotel stocks can use the coming numbers to test whether growth is holding.
Why Do API Maker, Garment Exporter and Hotel Stocks Have a Strong Roadmap in India?
API maker, garment exporter and hotel stocks have a strong roadmap in India because steady outsourcing of drug making, rising garment sourcing from India and strong hotel demand keep widening the market for these companies.
- Drug ingredients. Pharma firms source from reliable plants.
- Garments. Global brands add Indian suppliers.
- Hotels. Travellers choose trusted hotel brands.
Why Laurus Labs Features Among These API Maker, Garment Exporter and Hotel Stocks
Among the API maker, garment exporter and hotel stocks on this list, Laurus Labs is a Hyderabad-based pharmaceutical company with businesses in active ingredients, finished formulations, custom synthesis and biotechnology, with a leading position in anti-retroviral medicines.
In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%.
Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0.
Roadmap: The company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
What to watch: Follow the ramp-up of new capacity in formulations and the order flow in custom synthesis.
Why Pearl Global Industries Features Among These API Maker, Garment Exporter and Hotel Stocks
Among the drug ingredient, apparel sourcing and hospitality shares on this list, Pearl Global Industries is a Gurugram-based apparel manufacturer and exporter that makes garments for leading international brands from factories in India, Bangladesh, Vietnam and Indonesia.
The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2.
Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore.
Roadmap: The company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
What to watch: Watch order inflow from global brands and the ramp-up of newer factories.
Why Indian Hotels Company Features Among These API Maker, Garment Exporter and Hotel Stocks
Among the three companies on this list, Indian Hotels Company is India's largest hospitality company and part of the Tata Group, operating luxury, upscale and mid-market hotels and resorts under Taj, SeleQtions, Vivanta and Ginger, along with a food, dining and residences business.
Revenue rose from Rs 3,211 crore in FY22 to Rs 9,971 crore in FY26, a compound annual growth rate of 32.7%. Net profit grew from Rs 971 crore in FY23 to Rs 2,195 crore in FY26, which works out to a compound annual growth rate of 31.2%.
In the June 2026 quarter, revenue grew 15.1% year on year to Rs 2,419 crore, while net profit rose 22.4% to Rs 391 crore. The company has a return on equity of 16.0%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 108,181 crore. The stock trades at a P/E of 46.9, above the industry P/E of 37.9.
Roadmap: The company is growing mainly through management contracts and new signings, which add rooms without heavy capital outlay. Its strong brands, a pipeline of new hotels and rising travel and event demand support growth in occupancy and room rates.
What to watch: Track new room signings and openings and the pace of growth in its newer brands.
Laurus Labs vs Pearl Global Industries vs Indian Hotels Company on Key Financials
The table below sets the three API maker, garment exporter and hotel stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Laurus Labs | 4,951 | 6,868 | 8.5% | 890 | 13.0% |
| Pearl Global Industries | 2,747 | 5,062 | 16.5% | 270 | 5.3% |
| Indian Hotels Company | 3,211 | 9,971 | 32.7% | 2,195 | 22.0% |
Pearl Global Industries posts the highest return on equity in this group at 19.0%. Indian Hotels Company combines the largest FY26 revenue at Rs 9,971 crore with the fastest revenue growth, a 32.7% compound annual rate. A useful habit with API maker, garment exporter and hotel stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pharma ingredients, ready made clothing and luxury hotels stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Laurus Labs | 1,580 | 2,035 | 28.8% |
| Pearl Global Industries | 1,239 | 1,539 | 24.2% |
| Indian Hotels Company | 2,102 | 2,419 | 15.1% |
Key Risks to Check Before Investing in API Maker, Garment Exporter and Hotel Stocks
Every theme carries risks that deserve a check before any decision. For these API maker, garment exporter and hotel stocks, the main points are: Long-term drug ingredient, apparel sourcing and hospitality shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Currency moves. Export earnings move with the rupee.
- Travel cycles. Bookings and occupancy follow travel demand.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter API maker, garment exporter and hotel stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on API Maker, Garment Exporter and Hotel Stocks
API maker, garment exporter and hotel stocks reward patient research into demand, execution and financial strength. Laurus Labs, Pearl Global Industries and Indian Hotels Company each have a clear plan to grow. Based on the 17 November 2026 close, Laurus Labs trades at Rs 2,338, Pearl Global Industries at Rs 1,368.2 and Indian Hotels Company at Rs 901.55. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these API maker, garment exporter and hotel stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track API maker, garment exporter and hotel stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are API maker, garment exporter and hotel stocks?
Ans. API maker, garment exporter and hotel stocks are listed companies that make active drug ingredients and finished medicines for global pharma firms, make ready made garments for international brands, and run luxury and premium hotels across India. Their earnings depend on drug orders, garment export orders and hotel demand. This list looks at three of them, Laurus Labs, Pearl Global Industries and Indian Hotels Company, using reported FY22 to FY26 financials and the 17 November 2026 closing prices.
Which API maker, garment exporter and hotel stocks are covered in this list?
Ans. This list covers Laurus Labs, Pearl Global Industries and Indian Hotels Company. Based on the 17 November 2026 close, Laurus Labs traded at Rs 2,338, Pearl Global Industries at Rs 1,368.2 and Indian Hotels Company at Rs 901.55. Their return on equity ranges from 16.0% to 19.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.5% to 32.7%.
Why do API maker, garment exporter and hotel stocks have a strong future roadmap in India?
Ans. API maker, garment exporter and hotel stocks have a strong roadmap in India because steady outsourcing of drug making, rising garment sourcing from India and strong hotel demand keep widening the market for these companies. The main drivers are as follows. Drug ingredients. Pharma firms source from reliable plants. Garments. Global brands add Indian suppliers. Hotels. Travellers choose trusted hotel brands. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Laurus Labs performed financially?
Ans. Revenue rose from Rs 4,951 crore in FY22 to Rs 6,868 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 890 crore, a net margin of 13.0%. In the June 2026 quarter, revenue grew 28.8% year on year to Rs 2,035 crore, while net profit rose 124.7% to Rs 362 crore. The company has a return on equity of 16.8%, a debt to equity ratio of 0.48 and a market capitalisation of Rs 111,434 crore. The stock trades at a P/E of 102.2, above the industry P/E of 36.0. Looking ahead, the company has widened its range from anti-retroviral ingredients into oncology, cardiac and other therapies and has added capacity in formulations. Its custom synthesis and biotechnology arms add exposure to services for global drug developers.
How has Pearl Global Industries performed financially?
Ans. Revenue rose from Rs 2,747 crore in FY22 to Rs 5,062 crore in FY26, a compound annual growth rate of 16.5%. Net profit grew from Rs 70.1 crore in FY22 to Rs 270 crore in FY26, which works out to a compound annual growth rate of 40.1%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 1,539 crore, while net profit rose 51.4% to Rs 99.2 crore. The company has a return on equity of 19.0%, a debt to equity ratio of 0.65 and a market capitalisation of Rs 11,806 crore. The stock trades at a P/E of 38.9, above the industry P/E of 35.2. Looking ahead, the company benefits from global brands diversifying their sourcing away from a single country, and its multi-country footprint helps it serve them. Capacity additions and a growing retail brand portfolio add to its growth levers.
How has Indian Hotels Company performed financially?
Ans. Revenue rose from Rs 3,211 crore in FY22 to Rs 9,971 crore in FY26, a compound annual growth rate of 32.7%. Net profit grew from Rs 971 crore in FY23 to Rs 2,195 crore in FY26, which works out to a compound annual growth rate of 31.2%. In the June 2026 quarter, revenue grew 15.1% year on year to Rs 2,419 crore, while net profit rose 22.4% to Rs 391 crore. The company has a return on equity of 16.0%, a debt to equity ratio of 0.22 and a market capitalisation of Rs 108,181 crore. The stock trades at a P/E of 46.9, above the industry P/E of 37.9. Looking ahead, the company is growing mainly through management contracts and new signings, which add rooms without heavy capital outlay. Its strong brands, a pipeline of new hotels and rising travel and event demand support growth in occupancy and room rates.
What risks should investors check before buying API maker, garment exporter and hotel stocks?
Ans. Investors should check a few risks before buying API maker, garment exporter and hotel stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Currency moves. Export earnings move with the rupee. Travel cycles. Bookings and occupancy follow travel demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of API maker, garment exporter and hotel stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 17 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026

Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
18 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Large-Cap Cement Stocks Compared: UltraTech Cement vs Grasim vs JK Lakshmi Cement vs Ramco Cements vs Heidelberg Cement India on Price, Valuation, Q2 FY27 Results and Risks
Top Nifty Pharma Stocks Compared: Dr Reddy's vs Lupin vs Zydus Lifesciences vs Biocon vs Natco Pharma on Price, Valuation, Q2 FY27 Results and Risks
Top Specialty Chemical Stocks Compared: SRF vs Navin Fluorine vs Atul vs Vinati Organics vs Clean Science on Price, Valuation, Q2 FY27 Results and Risks
Top Paints Stocks Compared: Asian Paints vs Berger Paints vs Kansai Nerolac vs Indigo Paints vs JSW Dulux on Price, Valuation, Q2 FY27 Results and Risks
Top Diagnostics Stocks Compared: Dr Lal PathLabs vs Metropolis vs Thyrocare vs Krsnaa Diagnostics vs Vijaya Diagnostic on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





